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PAINTING THE SWAN BLACK: ON THE ART OF
RE-INVENTING INVENTIONS
Feroz Ali Khader*
The author argues that it is important to distinguishbetween genuinely
innovative 'Black Swans', and swans that are painted black, referring to
the increasingly common practice of making cosmetic or insignificant
modifications to existing innovations in order to obtain or extend patent
protection. This, the author argues, is especially significant in the
pharmaceuticalsector,since experiencehas shown beyond any doubt that
a substantialportion of its revenues emanatefrom incrementalinventions
as opposed to Black Swans. This is not likely to change either,given the
steadily widening gulf between investment in and returnfrom research
and development in the industry. The authorgoes on to identify a concrete
mechanism that is conducive to this process of weeding out Black Swans
from the impostors - pre-grant opposition strategy, and argues that its

meritsfar outweigh any possibledelay in the process of the grant of patents.
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1. INTRODUCTION
To many of us, a black swan defines an aberration. It is a strikingly odd (by
some accounts, extremely ugly), attention-grabbing, feathered creature that

*

The writer is a practicing advocate and the author of The Law of Patents- With a Special
Focus on Pharmaceuticalsin India (2007). The ideas expressed in this article will appear

in his new book, The Touchstone Effect The Impact of Pre-grant Opposition on Patents,
which will be published by LexisNexis in 2008.
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combines the gracefulness of a swan and the macabre of the colour black. A black
swan represents an extremely rare thing. The sighting of the black swan for the
first time in newly discovered Australia, centuries ago, overturned a general
statement derived from thousands of sightings of swans in the Old World - that

all swans were white. Until the discovery of what was already there down under,
the existence of a black swan was, to say the least, highly unexpected. It was much

like a white crow whose hypothetical existence was confined to unbelievable stories
and entertaining folklore. The idea of a black swan in popular thought has been
linked with unpredictable, extreme impact events that lie outside the realm of
regular expectation.
Black Swans have three defining characteristics - rarity, extreme impact and
retrospective predictability' Almost everything of some importance around us
will qualify for a Black Swan. 9/11 was an event which shared Black Swan traits.
The same could be said about the unexpected rise of Google and the fall of the
mighty Soviet Union. The cellular phone, which is now ubiquitous, was once a
Black Swan. The combination of low predictability and large impact makes the
Black Swan a desirable business outcome. Black Swans exist in all businesses. In
fact, businesses are constantly looking out for Black Swans. It could be the "next
big thing"", "the killer innovation" or the "wonder drug" which is new, non-obvious
and cannot be conceived by others. As the Black Swan logic makes what you do
not know far more relevant than what you do, the industry is quick in identifying
a Black Swan and quicker in protecting it. In the field of technology, Black Swan
innovations are protected by means of patents.

HI.

THE INNOVATION PROCESS

Peter Drucker, one of the foremost thinkers on management, characterised
innovation as the effort to create purposeful, focused change in an enterprise's
economic or social potential.2 Innovation refers to the process of bringing out new
inventions. For the purposes of patent law, which is concerned with inventions,
technological innovation can be broadly classified into two categories - radical
and incremental innovations. All innovations lie between these two extremes. Much
of the technological advancements that we see around us have been commercialised
through a clever mix of radical and incremental innovations. The life cycle of an
1.

N.N. Taleb, THE BLAcK SWAN: THE IPACrop THE HrOELY
House, 2007).

2.

P. Drucker, The DisciplineofInnovation, 76(6) HARv. Bus. REv. 149-57 (1998) availableat
http://www.businessweek.com/magazine/content/04
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innovative product begins as a radical innovation and continues through a number
of incremental innovations.
Take for instance the development of 3M's innovative product, Post-it. Post
it, when first developed, was so radical an innovation that 3M had problems in
marketing it. One can understand the astonishment of the stationery shoppers of
the 1970s who were curiously greeted by a little yellow rectangular block of sticky
papers. Once the radical innovation found acceptance in the market, 3M was quick
enough to develop Post-it with a series of incremental innovations like colourcoded Post-it and the Post-it Highlighter.
Disposable diapers have also followed more or less the same cycle.
What began as a replacement for traditional cloth-woven diapers, disposable
diapers have come a long way in handling some of the messy problems of
infancy. The commercial war between two pioneering companies, P&G and
Kimberly-Clark, saw this radical innovation being constantly upgraded
though a series of incremental innovations -'boy' diapers and 'girl' diapers
(which incidentally had nothing to do with identifying the gender of its users),
diapers with Velcro, elastic and cloth-feel as well as light-weight and scented
diapers which have a remarkable ability to camouflage unpleasantness when
stuff happens.
Apple's iPod also went through the pangs of radical-incremental shift while
growing up to be one of the most sought after technological gadgets of all time.
The truly radical iPod had to be supported by the iPod mini which was an
incremental innovation necessitated by the flooding of the market with cheap,
lower-end copied versions of the iPod.

I1.

BLACK SWAN INNOVATIONS

Radical innovations are very much like the Black Swans - outsides
which stand outside our normal expectations. Radical innovations are truly
remarkable, extremely rare and highly unpredictable-the Ipods and the Postits of every industry. Due to the predominant reliance on science and
technology, Black Swans are critical for the survival of the pharmaceutical
industry. The Black Swans of the pharmaceutical industry are better known
as "Blockbusters", for their ability to generate sales of over a billion dollars a
year. Quite rightly, the industry is looking for radical Black Swans, for the
invention of one such can make up for the huge amounts a pharmaceutical
company invests in R&D.
158
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A. SerendipitousBlack Swans
Way back in 1953, when researchers at 3M were developing a rubbery material for jet aircraft fuel lines, something surprising happened when a few drops of
the research material accidentally spilled on a researcher's canvas tennis shoe.
The material was so stubborn that it could not be wiped off the shoe. Instead of
worrying over the damage caused to the shoe, the researchers at 3M smartly concluded that they had stumbled upon a material that could repel both water and oil.
It took the genius of the people at 3M to develop this serendipitous discovery into
a ubiquitous house-hold product used as a stain repellent and soil-remover, known
to millions solely by its trade name - Scotchgard.
Every serendipitous discovery qualifies as a radical or Black Swan
Innovation. Serendipitous discoveries are common in all industries. It is often said
that chance favours the prepared mind to notice when something does not go as
expected, and to make sense of a stray event. As an industry built on a patentbased pharmaceutical development process, pharmaceuticals rely overly on
,unexpected and surprising effect' in patenting their products. Some significant
discoveries in the pharmaceutical industry have been a result of observing the
unexpected. Penicillin was discovered serendipitously. The same can be said about
Pfizer's anti-impotence drug, Viagra (sildenafil citrate), which was initially used
for treating hypertension and angina pectoris. Minoxidil's hair growing properties
were noticed fortuitously while treating some bald patients for hypertension. The
anaesthetic use of nitrous oxide (laughing gas) and ether were discovered
accidentally. Apart from thrilling researchers with the joy of the unexpected,
serendipitous discoveries also stand as testimonies to the unpredictable and
inconsistent manner in which innovation occurs in many industries. However,
the radical innovations in any industry have been few and far between. It is the
incremental innovations that dominate the industry, more so in the pharmaceutical
industry, where incremental innovations dominate radical innovations.

B. Incremental Innovation in Pharmaceuticals
Incremental innovations are minor changes and developments made to a
radical innovation. It is common industrial practice to invent a radical innovation
and develop it further incrementally. Incremental innovations are critical for the
3.

Though Scotchguard was sold in 1956, it was in 1971 that the inventors, Patsy Sherman
and Samuel Smith, obtained U.S. patent No. 3,574,791 'Block and Graft copolymers
containing Water-solvatable polar groups and flouroaliphatic groups', for the method
for treating carpets with Scotchgard. See Tony Davila et al, Making Innovation Work
- How to Manage it, Measure It and Profit from it 130-31 (Pennysylvania: Wharton
School Publishing 2006).
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development of a product. The pharmaceutical industry has witnessed the practice
of manufacturing versions of known drugs, known popularly as "me too" drugs.
"Me too" drugs are incarnations of incremental innovation. Though they are mere
versions of known drugs, they are marketed and protected like radical innovations.
Often they are sold as high-priced editions of existing drugs, claiming some
incremental advantage over what is already there. One of the best industry
examples of a "me too" drug replacing a radical drug was witnessed in the market
substitution of AstraZeneca's Nexium (esomerprazole) which successfully replaced
Prilosec, the original purple pill.4 Nexium is derived from Prilosec which contains
a racemic mixture of the D- and L- forms (isomers) of omeprazole. Nexium contains
only one of the isomers. "Me too" drugs are also seen in statins, a kind of drug
which lowers the level of cholesterol in the blood. Merck's Mevacor was the original
stating, which was released in the market in 1987. Today, the market is filled with
five more statins - Lipitor, Zocor, Pravachol, Lescol and Crestor - all manufactured
by leading pharmaceutical companies. Ironically, Mevacor is not the best-selling
statin. That honour goes to a me-too version of Mevacor, Pfizer's Lipitor whose
annual sales exceed US $13 billion.

IV. THE SEARCH FOR "BLOCKBUSTERS"
The pharmaceutical industry has been looking out for blockbusters.
Blockbusters mean easy profit. The lure of huge pay-offs has enticed the industry
to look out for potential blockbuster drugs. Lipitor earns Pfizer annual revenue in
excess of US $13 billion. AstraZeneca's Prilosec (used for the treatment of heartburn)
earned US $6 billion in 2001, the year in which its patent expired.
In no other field of technology does innovation play a more significant role
than in the pharmaceutical sector. Empirical research has repeatedly demonstrated
the importance of innovation and the need to protect these innovations in the
pharmaceutical industry. Due to the unique positioning of the pharmaceutical
industry, three factors affect the way in which the industry operates. First, the
high costs of R&D have resulted in expensive drugs - drugs which need more than
a billion dollars to develop. Secondly, it is relatively easy to duplicate these drugs
by reverse engineering, as pharmaceuticals are chemicals used in the treatment of
ailments and diseases and are as such susceptible to all the technical risks chemical
compounds are exposed to. Thirdly, the indispensability of public health and the
willingness of the consuming public to pay any price for the medicines have made
the pharmaceutical industry a key player in seeking patents. The innovative
4.

See http//www.purplepill.com/about-nexium/.
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strength of the pharmaceutical industry can therefore not be underestimated. The
impact of blockbuster drugs, drugs whose annual turnover are in billions, symbolise
the importance of innovation in the pharmaceutical sector.
Despite the huge investments made by the pharmaceutical industry in R&D,

the output of innovative drugs has been few and far between. The real sources of
innovation have been academic institutions, small biotech companies and publicly
funded research organisations. Some of the best-selling drugs in the industry have
either originated or benefited from publicly funded research. For instance, AZT, the
first AIDS drug, was developed by the National Cancer Institute and Duke University
and later licensed to GSK. Taxol (paclitaxel), a leading cancer drug, was developed
by the National Cancer Institute and Florida State University and later licensed to
Bristol-Myers Squibb. Amgen's Epogen was developed by the University of Chicago
and the University of Columbia. Novartis' Gleevec benefited from the research done
by NIH-funded university researchers. The above illustrations are representative of
how innovation happens in the pharmaceutical industry.

V. RE-INVENTING

DRUGS

Aspirin changed many things for the pharmaceutical industry. When
acetylsalicylic acid was discovered in 1 9 century, nothing significant happened

till Bayer skilfully marketed the drug into a bestseller. Aspirin soon lost out to
other analgesics like Paracetamol and Ibuprofen. The latter part of the 2 0th century
witnessed the resurgence of the drug. Aspirin was reinvented when blood-thinning
properties were discovered, thereby increasing the demand of the old drug.
Discoveries such as these have shifted the focus of the industry from inventing
new drugs to discovering new uses of known drugs and to lobbying for patent
protection for such new uses.
The pharmaceutical industry has been playing it safe when it comes to huge
investments in R&D. There is a great focus in the industry on new uses of known
substances. The most spectacular example is Pfizer's anti-impotence drug Viagra
(Sildenafil citrate), which was originally developed as a cardiovascular drug. Pfizer
applied the drug for a new use to combat the problem of erectile dysfunction
which made the drug a best-seller. Despite the world-renowned popularity of the
drug, the drug does not enjoy patent protection in many jurisdictions. It does not
enjoy patent protection in the UK, China and India, to name a few. This is due to
the fact that the national jurisdictions have provisions in their law by which a new
use of a known compound is treated as obvious and lacking inventive steps. The
novelty is confined to novelty of use. Despite the restrictions on obviousness and
161
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some special laws which oppose the grant of patents for new uses of known
substances (like s. 3(d) of the Indian Patents Act 1970), pharmaceutical companies
continue to place heavy reliance on developing new forms and new uses of old
and known drugs. It is no surprise that the world's largest pharmaceutical company,
Pfizer, has as its future growth plan the examination of drug targets whose role in
diseases is already well established?

VI.

RELIANCE ON INCREMENTAL INNOVATION

The overwhelming reliance on incremental innovation by the pharmaceutical
industry is attributable largely to the industry's need to play safe. Johnson &
Johnson opted for such a strategy by relying on line extensions, cost-cutting and
acquisitions to hold off the competition as there were only a few new drugs in the
pipeline in the short term.'
A. Investment in R&D
The investments in R&D by the leading pharmaceutical companies have
been soaring through the years. In the year 2002, the top companies invested
more than US $35 billion in R&D. Industry sponsored studies have also
increasingly raised the bench mark for developing a new molecule. In 2001, a
study conducted by Tufts University concluded that the average cost of
pharmaceutical R&D was US $802 million to develop a new drug and bring it to

the market. The 2008 study by Tufts University set the cost to develop a new
biopharmaceutical at above US $1 billion. The study concludes that the total
biopharmaceutical R&D costs include the cost of molecules that fail in testing
and the time cost of investing in development years before any potential returns

can be earned. Time costs account for more than half of the total cost of
recombinant proteins and monoclonal antibodies that entered the clinical testing
pipeline from 1990 to 20037
B. Dwindling Pipelines
But the huge expenditure on R&D has not translated into the development
of new drugs. This is evident from the 2003 report of the United States Food and
Drug Authority, as detailed in Table 1 below.

5.
6.

7.

A.J. Barrett et al., Feeding the Pipeline, Bus. WK. 78-82 (2003).
F. Amer & A. Weintraub, ]&J: Toughing out the drought, Bus. WK. 84-85, 64 (Jan, 2004).
Oumoor (Tufts Centre for the Study of Drug Development, 2008) availableat http://

esdd.tufts.edu.
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Table 1: New Drugs Approved by the US FDA between 1996 and 2003
Year

New Drugs Approved (NDA)

New Molecular Entities (NME)

2003

14

9

2002

11

7

2001

10

7

2000

20

9

1999

28

19

These issues faced by pharmaceuticals have led the industry to devise ways

of re-inventing inventions. Major pharmaceutical companies are big organisations
which need huge profits to sustain the growth rate. With the pipeline of new drugs
dwindling over the years and with many products going off patent protection
soon, pharmaceutical companies have resorted to new ways of patenting old
inventions.

VI.

PAINTING THE SwAN BLACK

In the field of innovation, a Black Swan refers to a rare, high impact and
unpredictable innovation that can bring unprecedented success to any business.

Most of the path-breaking, radical technologies that we see around us are Black
Swan Innovations. And every technology company is looking out for Black Swans
and the means of protecting them. The law of patents offers the mostcomprehensive means of protecting the Black Swan. While it is one thing to
offer patent protection for the genuine Black Swans - the real, radical innovations
that are novel and non-obvious, it is entirely another thing when old and obvious
innovations are patented as new - an ordinary swan painted black! "Painting
the swan black" metaphorically refers to passing of a white swan as black
(patenting inventions that are obvious) or doing a paint job to refurbish an old
black swan to look new (making superficial changes to an earlier invention to
qualify for a fresh grant). Both can have adverse affect on business and the
development of technology.
If used effectively, pre-grant opposition procedure can act as a touchstone

to test the genuineness of an invention. It can be used to separate the real Black
Swans from the ones that are painted black. While pre-grant opposition could
be criticised, as it is done in the United States, on the ground that it could
163
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frivolously delay the grant of a patent, the benefits that arise out of having a pregrant opposition procedure in a patent system far outweigh the ills that malign
it. Frivolous pre-grant opposition could be disciplined by imposing punitive
costs on the pre-grant opponent? It is an inherent disposition of the patent system
that it balances the tension between rewarding some inventors at the cost of
inhibiting the activities of others. Pre-grant opposition should be seen as yet

another balancing act which counterweighs the need to bring outside information
into the patent office against the probable delay in asserting one's exclusivity
over the patent when it is granted.9

8.

9.

See Enkay Rubber's Application, India Patent No. 193339 (1342/Del/1999), where the
Controller observed that the opponent had at every point of time requested for an
adjournment and had adopted various ways to delay the proceedings and granted
compensatory costs of Rs32,000 for delay in the grant of patent caused by the opponent.
This assertion of exclusivity is nothing but stopping others from using the invention.
Pre-grant opposition does not eat into the life of a patent as the life of a patent accrues
from the date of making the application. Pre-grant opposition, at best, delays the

right of the applicant to stop others from using and exploiting the invention which

accrues only after the grant of the patent.
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